Update in addiction medicine for the generalist

Journal of General Internal Medicine

Volumn 22, Issue 8, 2007, Pages 1190-1194

  Gordon, Adam J ^a,b,c   Sullivan, Lynn E ^d   Alford, Daniel P ^e   Arnsten, Julia H ^f   Gourevitch, Marc N ^g   Kertesz, Stefan G ^h   Kunins, Hillary V ^f   Merrill, Joseph O ⁱ   Samet, Jeffrey H ^e   Fiellin, David A ^d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Primary health care; Review literature; Substance related disorders

Indexed keywords

ACAMPROSATE; AMFEBUTAMONE; BUPRENORPHINE; METHADONE; NALTREXONE; NICOTINE; OPIATE; VARENICLINE;

ADDICTION; ALCOHOLISM; CLINICAL PRACTICE; CLINICAL TRIAL; HUMAN; OUTCOME ASSESSMENT; REVIEW; TOBACCO DEPENDENCE;

ALCOHOLISM; HUMANS; OPIOID-RELATED DISORDERS; PHYSICIANS, FAMILY; SUBSTANCE-RELATED DISORDERS; TOBACCO USE DISORDER;

EID: 34447125019     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-007-0133-4     Document Type: Review

References (41)

1. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291(10):1238-45.
2. Substance Abuse and Mental Health Services Administration Office of Applied Studies. Results from the 2004 Survey on Drug Use and Health: National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration Office of Applied Studies; 2005. DHHS publication no. SMA 05-4062, NSDUH series H-28.
3. Grant BF, Dawson DA, Stinson FS, et al. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend. 2004;74(3):223-34.
4. Saitz R. Clinical practice. Unhealthy alcohol use. N Engl J Med. 2005;352(6):596-607.
5. Whitlock EP, Polen MR, Green CA, Orleans T, Klein J. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140(7):557-68.
6. Pettinati HM, Weiss RD, Miller WR, Donovan D, Denise B, Rounsaville BJ. COMBINE Monograph Series, Volume 2. Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2004. DHHS publication no. (NIH) 04-5289.
7. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence. JAMA. 2006;295(17):2003-17.
8. Pettinati HM, Weiss RD, Dundon W, et al. A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol Suppl. 2005;(15):170-8.
9. Miller WR. Combined behavioral intervention manual. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2004. NIH publication no. 04-5288.
10. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617-25.
11. Miller WR, Walters ST, Bennett ME. How effective is alcoholism treatment in the United States? J Stud Alcohol. 2001;62(2):211-20.
12. Tucker JA, Roth DL. Extending the evidence hierarchy to enhance evidence-based practice for substance use disorders. Addiction. 2006;101(7):918-32.
13. Agency for Healthcare Research and Quality. The Guide to Clinical Preventive Services, 2005. Recommendations of the U.S. Preventive Services Task Force. Available at http://www.preventiveservices.ahrq.gov. Accessed December 1, 2006.
14. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348(26):2635-45.
15. National Institute on Alcohol Abuse and Alcoholism. Helping Patients Who Drink Too Much: A Clinician's Guide. Rockville, MD: U.S. Department of Health & Human Services; 2005. NIH publication no. 05-3769.
16. Fleming MF. In search of the Holy Grail for the detection of hazardous drinking. J Fam Pract. 2001;50(4):321-2.
17. Gordon AJ, Maisto SA, McNeil M, et al. Three questions can detect hazardous drinkers. J Fam Pract. 2001;50(4):313-20.
18. Canagasaby A, Vinson DC. Screening for hazardous or harmful drinking using one or two quantity-frequency questions. Alcohol Alcohol. 2005;40(3):208-13.
19. Williams R, Vinson DC. Validation of a single screening question for problem drinking. J Fam Pract. 2001;50(4):307-12.
20. Vinson DC. Screening question for alcohol abuse. Am Fam Physician. 2002;66(2):209.
21. Taj N, Devera-Sales A, Vinson DC. Screening for problem drinking: does a single question work? J Fam Pract. 1998;46(4):328-35.
22. National Center For Chronic Disease Prevention and Health Promotion, Center for Disease Control. Percentage of adults who were current, former, or never smokers, overall and by sex, race, Hispanic origin, age, and education, National Health Interview Surveys, selected years-United States, 1965-2000. Available at: http://www.cdc.gov/tobacco/research_data/adults_prev/adstat1print. htm. Accessed October 5, 2006.
23. Centers for Disease Control and Prevention. Smoking-attributable mortality and years of potential life lost-United States, 1984. MMWR Morb Mortal Wkly Rep. 1997;46(20):444-51.
24. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2004;(1):CD003041.
25. Friedenreich CM. Methods for pooled analyses of epidemiologic studies. Epidemiology. 1993;4(4):295-302.
26. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377-84.
27. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
28. National Cholesterol Education Program Expert Panel on Detection EaToHBCiAATPI. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421.
29. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335(8693):827-38.
30. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-39.
31. The Tobacco Use and Dependence Clinical Practice Guideline Panel SaCR. A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report. JAMA. 2000;283(24):3244-54.
32. Thorndike AN, Rigotti NA, Stafford RS, Singer DE. National patterns in the treatment of smokers by physicians. JAMA. 1998;279(8):604-8.
33. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47-55.
34. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56-63.
35. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):64-71.
36. Johnston LD, O'Malley PM, Backman JG, Schulenberg JE. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings. Bethesda, MD: National Institute on Drug Abuse; 2005.
37. Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2005;35(12):1747-59.
38. Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage. 2004;28(2):176-88.
39. Turner BJ, Laine C, Lin YT, Lynch K. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med. 2005;165(15):1769-76.
40. Institute of Medicine. Improving the Quality of Healthcare for Mental and Substance-use Conditions: The Quality Chasm Series. Washington, DC: The National Academies Press; 2005.
41. Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: The National Academies Press; 2001.